Tabalumab (LY2127399) is a humanised monoclonal antibody targeting BAFF that neutralises both soluble and membrane-bound forms of BLyS and affects B-cell populations, and can be used for research into autoimmune diseases such as rheumatoid arthritis, kidney failure, and systemic lupus erythematosus.

Methods:
T1165.17 cells were treated with Tabalumab at concentrations ranging from 1 to 100 ng/mL and incubated for 44 hours to assess its neutralization of soluble human, cynomolgus monkey, and rabbit BAFF.
Results:
Tabalumab effectively neutralized soluble BAFF in T1165.17 cells with IC₅₀ values of 104 pM (human), 143 pM (cynomolgus monkey), and 176 pM (rabbit), respectively. [1]

Methods:
In human BAFF transgenic mice, a single subcutaneous injection of Tabalumab was given at a dose of 500 µg per mouse.
Results:
Tabalumab significantly reduced splenic B-cell counts between days 4 and 8, and decreased p52 levels, which returned to near the baseline of BAFF transgenic mice by day 23. [1]